Biotinylated Human CD30/TNFRSF8 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02505P-100UG
Biotinylated CD30 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Biotinylated Human CD30/TNFRSF8 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02505P-100UG
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Biotinylated Human CD30/TNFRSF8 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Phe19-Lys379. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | P28908 |
Target Symbol | CD30/TNFRSF8 |
Synonyms | CD30; CD30KI-1; CD30L receptor; TNFRSF8; D1S166EKi-1; CD30KI-1 |
Species | Human |
Expression System | HEK293 |
Tag | C-His-Avi |
Expression Range | Phe19-Lys379 |
Mol. Weight | The protein has a predicted MW of 41.3 kDa. Due to glycosylation, the protein migrates to 70-100 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Anti-CD30 Antibody, hFc Tag at 0.5ug/ml (100ul/well) on the plate. Dose response curve for Biotinylated Human CD30, His Tag with the EC50 of 11.5ng/ml determined by ELISA (QC Test). Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin's lymphomas (NHLs). |